title: Survival in unresectable AJCC stage I and II HCC and the effect of DEB-TACE: SEER versus tertiary cancer center cohort study.
abstract: OBJECTIVE
  To evaluate overall survival (OS) in unresectable American Joint Committee on Cancer (AJCC) stage I/II hepatocellular carcinoma (HCC) treated with drug-eluting-bead transarterial chemoembolization (DEB-TACE) versus best supportive care.
  
  
  METHODS
  OS in consecutive patients with AJCC stage I/II unresectable HCC diagnosed in 2005-2010 who underwent DEB-TACE and similar patients from SEER with no surgery/radiation recommended/performed was evaluated.
  
  
  RESULTS
  Median OS from HCC diagnosis was 28.9 months (DEB-TACE) versus 10.0 months (SEER), p < 0.0001. Median OS was 36.3 months (DEB-TACE) versus 12.0 months (SEER) in AJCC I, and 27.9 months (DEB-TACE) versus 10.0 months (SEER) in AJCC II, p < 0.0001. Significant independent prognostic factors for OS were single primary tumor, no vascular invasion, normal α-fetoprotein and DEB-TACE.
  
  
  CONCLUSIONS
  DEB-TACE in patients with unresectable AJCC stage I/II HCC was a significant independent prognostic factor for greater OS in a population-based study.
authors.affiliation: Interventional Radiology, Department of Radiology & Biomedical Imaging, Yale University School of Medicine, New Haven, CT, USA.
authors.forename: Minzhi
authors.initials: M
authors.lastname: Xing
authors.affiliation: Interventional Radiology & Image-guided Medicine, Department of Radiology & Imaging Sciences, Emory University School of Medicine, Atlanta, GA, USA.
authors.forename: Nima
authors.initials: N
authors.lastname: Kokabi
authors.affiliation: Interventional Radiology & Image-guided Medicine, Department of Radiology & Imaging Sciences, Emory University School of Medicine, Atlanta, GA, USA.
authors.forename: Hasmukh J
authors.initials: HJ
authors.lastname: Prajapati
authors.affiliation: Interventional Radiology, Department of Radiology, University of Pittsburgh, PA, USA.
authors.forename: Orrie
authors.initials: O
authors.lastname: Close
authors.affiliation: Interventional Radiology, Department of Radiology & Biomedical Imaging, Yale University School of Medicine, New Haven, CT, USA.
authors.forename: Johannes M
authors.initials: JM
authors.lastname: Ludwig
authors.affiliation: Interventional Radiology, Department of Radiology & Biomedical Imaging, Yale University School of Medicine, New Haven, CT, USA.|Yale Cancer Center, New Haven Hospital, 333 Cedar Street, New Haven, CT 06510, USA.
authors.forename: Hyun S
authors.initials: HS
authors.lastname: Kim
mesh_terms: D000368:Aged; D006528:Carcinoma, Hepatocellular / Q000401:mortality* / Q000628:therapy*; D016461:Chemoembolization, Therapeutic / Q000379:methods*; D015331:Cohort Studies; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000401:mortality* / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D018426:SEER Program / Q000706:statistics & numerical data*; D012720:Severity of Illness Index; D016019:Survival Analysis; D062606:Tertiary Care Centers / Q000706:statistics & numerical data; D016896:Treatment Outcome; D014481:United States / Q000453:epidemiology
keywords: AJCC staging; SEER; chemoembolization; drug-eluting-bead transarterial chemoembolization; hepatocellular carcinoma; locoregional therapy